GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes

Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus

(2014) A. Michael Lincoff et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer

(2013) J R Colca et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dual Peroxisome Proliferator-Activated Receptor  /  Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

(2013) B. Cariou et al.   DIABETES CARE

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2013) Bart Staels et al.   HEPATOLOGY

Harnessing the benefits of PPARβ/δ agonists

(2013) Louise S. Mackenzie et al.   LIFE SCIENCES

A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use

(2013) Sihao Liu et al.   NATURE

The role of hepatokines in metabolism

(2013) Norbert Stefan et al.   Nature Reviews Endocrinology

Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models

(2012) Ying Chen et al.   DIABETES

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

(2012) Naga Chalasani et al.   HEPATOLOGY

Medication Adherence in Type 2 Diabetes: The ENTRED Study 2007, a French Population-Based Study

(2012) Michel Tiv et al.   PLoS One

Protection from liver fibrosis by a peroxisome proliferator-activated receptor   agonist

(2012) K. Iwaisako et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Thiazolidinediones and PPARγ agonists: time for a reassessment

(2012) Bertrand Cariou et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

(2011) E. Boettcher et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Peroxisome Proliferator–Activated Receptor-α Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice

(2011) Fanny Lalloyer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Roles of PPARs in NAFLD: Potential therapeutic targets

(2011) Anne Tailleux et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Cellular and molecular mechanisms of metformin: an overview

(2011) Benoit Viollet et al.   CLINICAL SCIENCE

Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment: The FIELD Study

(2011) R.-D. Ting et al.   DIABETES CARE

Effects of the New Dual PPAR /  Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism

(2011) B. Cariou et al.   DIABETES CARE

Do fibrates truly preserve kidney function?

(2011) Suneel M. Udani et al.   Nature Reviews Endocrinology

Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment

(2011) Briohny W. Smith et al.   Nature Reviews Endocrinology

The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact

(2011) Esther Phielix et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors

(2010) Fanny Lalloyer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome

(2010) Renata Belfort et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A position statement on NAFLD/NASH based on the EASL 2009 special conference

(2010) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Roles of liver innate immune cells in nonalcoholic fatty liver disease

(2010) Yu-Tao Zhan   WORLD JOURNAL OF GASTROENTEROLOGY

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

(2008) Catherine Postic et al.   JOURNAL OF CLINICAL INVESTIGATION

Fibrates and future PPARα agonists in the treatment of cardiovascular disease

(2008) Bart Staels et al.   Nature clinical practice. Cardiovascular medicine

Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses

(2007) Leena Juurinen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM